Mark Glaum
Allergy & Immunology · Tampa, FLNPI 1073598744
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $253,877 of the $336,551 with a category attached, or 75.4%. 28 manufacturers reported payments, led by CSL Behring at 27.1% of the total. Among allergy & immunology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $730.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$91K
- Shire North American Group Inc$77K
- Takeda Pharmaceuticals U.S.A., Inc.$74K
- Biocryst US Sales Co., LLC$65K
- Ionis Pharmaceuticals, Inc.$18K
- Biocryst Pharmaceuticals, Inc.$3K
- plus $7K from 22 others
What the payments were for
- Consulting fees$42,51613%
- Speaking & faculty fees$253,87775%
- Travel & lodging$31,1959%
- Food & beverage$8,3612%
- Education$6020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 110 | $91,281 |
| Shire North American Group Inc | 118 | $76,880 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $74,220 |
| Biocryst US Sales Co., LLC | 49 | $65,274 |
| Ionis Pharmaceuticals, Inc. | 21 | $18,232 |
| Biocryst Pharmaceuticals, Inc. | 3 | $3,430 |
| Genentech USA, Inc. | 3 | $1,767 |
| Alk-abello, Inc | 2 | $1,609 |
| Blueprint Medicines Corporation | 1 | $1,485 |
| Novartis | 11 | $481 |
| Regeneron Healthcare Solutions, Inc. | 9 | $451 |
| GSK | 16 | $304 |
| Sanofi-aventis U.S. LLC | 2 | $191 |
| Pfizer | 10 | $188 |
| AstraZeneca | 9 | $159 |
| Sanofi | 5 | $148 |
| Amgen | 3 | $68 |
| Pharming Healthcare, Inc. | 3 | $65 |
| Covis Pharma GmbH | 3 | $59 |
| LEO Pharma Inc. | 2 | $50 |
| Optinose US, Inc. | 3 | $45 |
| Kaleo, Inc. | 3 | $43 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| Grifols USA, LLC | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| AbbVie | 1 | $18 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$336,551 in reported general payments places this provider in the 95th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $678,316 |
| HaegardaC1 Esterase Inhibitor | 26 | $599,109 |
| Dupixent SyringeDupilumab | 12 | $44,636 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $40,926 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $17,225 |
| Spiriva RespimatTiotropium Bromide | 21 | $15,825 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,133 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,098 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $2,980 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,201 |
| Azelastine Hcl | 67 | $2,136 |
| Ipratropium Bromide | 45 | $1,979 |
| Epinephrine | 12 | $1,836 |
| Fluticasone Propionate | 62 | $1,472 |
| Montelukast Sodium | 93 | $1,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $74,220 | $678,31613 claims |
| CSL BehringHaegarda | $91,281 | $599,10926 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $304 | $47,05954 claims |
| AstraZenecaSymbicort | $159 | $17,22548 claims |
| Boehringer IngelheimSpiriva Respimat | $11 | $15,82521 claims |
| Hikma Pharmaceuticals USAEpinephrine | $19 | $1,83612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Tampa
- Dennis LedfordTampa$1.2M
- Thomas CasaleTampa$382K
- Juan Carlos CardetTampa$180K
- Farnaz TabatabaianTampa$76K
- Seong ChoTampa$42K
- Richard LockeyTampa$27K
- Ammar HatabTampa$14K
- Richard SiegelTampa$13K
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.